CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $679,000 | -19.4% | 5,570 | +1.3% | 0.00% | 0.0% |
| Q4 2020 | $842,000 | +83.0% | 5,500 | 0.0% | 0.00% | – |
| Q3 2020 | $460,000 | +13.9% | 5,500 | 0.0% | 0.00% | – |
| Q2 2020 | $404,000 | +73.4% | 5,500 | 0.0% | 0.00% | – |
| Q1 2020 | $233,000 | -30.4% | 5,500 | 0.0% | 0.00% | – |
| Q4 2019 | $335,000 | +48.9% | 5,500 | 0.0% | 0.00% | – |
| Q3 2019 | $225,000 | +10.8% | 5,500 | +27.9% | 0.00% | – |
| Q2 2019 | $203,000 | +31.8% | 4,300 | 0.0% | 0.00% | – |
| Q1 2019 | $154,000 | +22.2% | 4,300 | -2.3% | 0.00% | – |
| Q4 2018 | $126,000 | -11.3% | 4,400 | +37.5% | 0.00% | – |
| Q3 2018 | $142,000 | -24.5% | 3,200 | 0.0% | 0.00% | – |
| Q2 2018 | $188,000 | +46.9% | 3,200 | +14.3% | 0.00% | – |
| Q1 2018 | $128,000 | +70.7% | 2,800 | -12.5% | 0.00% | – |
| Q4 2017 | $75,000 | – | 3,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |